Paclitaxel: a review of adverse toxicities and novel delivery strategies

Authors: Marupudi, Neena I; Han, James E; Li, Khan W; Renard, Violette M; Tyler, Betty M; Brem, Henry

Source: Expert Opinion on Drug Safety, Volume 6, Number 5, September 2007 , pp. 609-621(13)

Buy & download fulltext article:

Price: $99.00 plus tax (Refund Policy)

Abstract:

Better known as Taxol^® (Bristol-Myers Squibb), paclitaxel is the first member of the taxane family to be used in cancer chemotherapy. The taxanes exert their cytotoxic effect by arresting mitosis through microtubule stabilization, resulting in cellular apoptosis. The use of paclitaxel as a chemotherapeutic agent has become a broadly accepted option in the treatment of patients with ovarian, breast and non-small cell lung cancers, malignant brain tumors, and a variety of other solid tumors. However, significant toxicities, such as myelosuppression and peripheral neuropathy, limit the effectiveness of paclitaxel-based treatment regimens. This review addresses the toxicities associated with paclitaxel treatment and describes existing and future strategies of paclitaxel administration directed at limiting these toxicities.

Keywords: adverse effects; cancer; paclitaxel; safety; toxicity

Document Type: Research article

DOI: http://dx.doi.org/10.1517/14740338.6.5.609

Publication date: 2007-09-01

More about this publication?